These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 16540725)

  • 41. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome.
    Goteri G; Olivieri A; Ranaldi R; Lucesole M; Filosa A; Capretti R; Pieramici T; Leoni P; Rubini C; Fabris G; Lo Muzio L
    Int J Immunopathol Pharmacol; 2006; 19(2):421-31. PubMed ID: 16831308
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.
    Kinoshita T; Nagai H; Murate T; Saito H
    J Clin Oncol; 1998 Dec; 16(12):3916. PubMed ID: 9850038
    [No Abstract]   [Full Text] [Related]  

  • 44. New monoclonal antibody approved as lymphoma therapy.
    Am J Health Syst Pharm; 1998 Jan; 55(2):110. PubMed ID: 9465971
    [No Abstract]   [Full Text] [Related]  

  • 45. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis.
    Foran JM; Norton AJ; Micallef IN; Taussig DC; Amess JA; Rohatiner AZ; Lister TA
    Br J Haematol; 2001 Sep; 114(4):881-3. PubMed ID: 11564080
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
    Hiraga J; Tomita A; Sugimoto T; Shimada K; Ito M; Nakamura S; Kiyoi H; Kinoshita T; Naoe T
    Blood; 2009 May; 113(20):4885-93. PubMed ID: 19246561
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
    Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M
    J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214
    [TBL] [Abstract][Full Text] [Related]  

  • 48. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
    Hao LC; Zhang LZ
    Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
    [No Abstract]   [Full Text] [Related]  

  • 50. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond.
    Bello C; Sotomayor EM
    Hematology Am Soc Hematol Educ Program; 2007; ():233-42. PubMed ID: 18024635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan.
    Tobinai K
    Int J Hematol; 2002 Dec; 76(5):411-9. PubMed ID: 12512835
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).
    Yokose N; Shioi Y; Sugisaki Y; Ohaki Y; Ogata K; Dan K
    Leuk Lymphoma; 2006 Jul; 47(7):1415-7. PubMed ID: 16923582
    [No Abstract]   [Full Text] [Related]  

  • 53. Prognostic Effect of CD20 Expression in Adult B-cell Acute Lymphoblastic Leukemia.
    Esteban RE; Christianne B; Alvaro A; Demichelis-Gómez R
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):361-367. PubMed ID: 29544762
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-CD20 monoclonal antibodies: beyond B-cells.
    Avivi I; Stroopinsky D; Katz T
    Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy.
    Tomita A; Hiraga J; Kiyoi H; Ninomiya M; Sugimoto T; Ito M; Kinoshita T; Naoe T
    Int J Hematol; 2007 Jul; 86(1):49-57. PubMed ID: 17675267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
    Zhou X; Hu W; Qin X
    Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ublituximab for the treatment of CD20 positive B-cell malignancies.
    Babiker HM; Glode AE; Cooke LS; Mahadevan D
    Expert Opin Investig Drugs; 2018 Apr; 27(4):407-412. PubMed ID: 29609506
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
    Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
    Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease.
    Younes A; Romaguera J; Hagemeister F; McLaughlin P; Rodriguez MA; Fiumara P; Goy A; Jeha S; Manning JT; Jones D; Abruzzo LV; Medeiros LJ
    Cancer; 2003 Jul; 98(2):310-4. PubMed ID: 12872350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.